Plain-English translation of NCT06574594 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Rheumatoid Arthritis research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This research trial is testing whether pausing arthritis medication after receiving Shingrix (a shingles vaccine) helps people with rheumatoid arthritis develop stronger protection against shingles. Some participants will continue taking their arthritis medication throughout, while others will pause it for 2 weeks after each vaccine dose. The study will measure how well each group's immune system responds to the vaccine.
People with rheumatoid arthritis often take medications that can weaken their immune response, which may reduce how well vaccines work. Researchers want to understand if temporarily stopping this medication during vaccination could help these patients build better protection against shingles without harming their arthritis control.
You likely qualify if…
You likely don't qualify if…
You will receive the shingles vaccine twice: at your first visit and again 2 months later. You'll visit the clinic four times total (at the start, 2 months, 3 months, and 6 months) for blood samples to measure your immune response. Depending on which group you're assigned to, you'll either keep taking your arthritis medication throughout or stop it for 2 weeks after each vaccine dose.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
South Korea
Sponsor
Konkuk University Medical Center
Enrollment target
~110 participants
Started
August 2024
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
19 Years and older
Last updated on clinicaltrials.gov in August 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Hong Ki Min, MD, PhD
Konkuk University Medical Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.